Analysts Offer Insights on Healthcare Companies: Spark Therapeutics (ONCE), Intuitive Surgical (ISRG) and Globus Medical (GMED)


Analysts fell to the sidelines weighing in on Spark Therapeutics (ONCE), Intuitive Surgical (ISRG) and Globus Medical (GMED) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Spark Therapeutics (ONCE)

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Spark Therapeutics on January 7. The company’s shares closed yesterday at $44.18, close to its 52-week low of $34.53.

According to TipRanks.com, Kasimov is a 2-star analyst with an average return of -0.2% and a 38.7% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Allogene Therapeutics Inc, and Global Blood Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spark Therapeutics with a $59.10 average price target, which is a 33.8% upside from current levels. In a report issued on January 7, Credit Suisse also maintained a Hold rating on the stock with a $44 price target.

.

See today’s analyst top recommended stocks >>

Intuitive Surgical (ISRG)

In a report released yesterday, Sean Lavin from BTIG maintained a Hold rating on Intuitive Surgical. The company’s shares closed yesterday at $517.11.

Lavin wrote:

“Achievable ISRG reported preliminary 4Q18 revenue of $1.047B (17% y/y), in line with our forecast of $1.046B and topping consensus’ estimates of $1.028B. Procedure growth of 19% in Q4 came in just above the Street’s 18.6% forecast. The sales breakout for 4Q included $539M in instrument revenue, $341M in system sales, and $167M for service, roughly matching Street estimates for instrument and service sales and beating forecasted system sales by $22M. 2019 guidance calls for 13-17% procedure growth, in line with our 14.7% forecast and consensus growth of 15.4%. This beat on revenue and procedure growth matched our expectations going into the report. The total revenue beat, strong system unit sales, and in-line 2019 guidance seem to be lifting ISRG shares, despite the lack of a larger outperformance on Q4 procedure growth and instrument revenue.”

According to TipRanks.com, Lavin is a 5-star analyst with an average return of 9.2% and a 57.1% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.

Intuitive Surgical has an analyst consensus of Strong Buy, with a price target consensus of $603.13.

Globus Medical (GMED)

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Hold rating on Globus Medical. The company’s shares closed yesterday at $42.68.

Zimmerman observed:

“with Neutral GMED preannounced preliminary 4Q18 rev. of $195.5M, up +11.1% Y/Y, beating BTIG and Consensus est. of $189.2M and $188.2M, respectively. FY18 rev. is expected to be $712.5M, up +12.0% Y/Y, beating BTIG and Consensus est. of $706.2M and $705.2M. Emerging Technologies rev. for the quarter is expected to be $14.8M, up +35% Y/Y, just below BTIG and Consensus est. of $15.0M and $14.9M, respectively. Backing this out, we est. Spinal Implant revenue of $180.7M for 4Q, up +9.5% Y/Y, above BTIG and Consensus est. of $176.6M and $173.2M. We note that a portion of 4Q17 Emerging Tech rev. was moved to Spinal Implant rev. (~$1.3M) resulting in the 35% Y/Y growth comparison. Initial FY19 guidance of $770.0M in rev. compared to BTIG and Consensus est. of $768.7M and $764.1M, and EPS of $1.72, compared to BTIG and Consensus est. of $1.71 and $1.73.”

According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 21.0% and a 50.6% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.

Globus Medical has an analyst consensus of Moderate Buy, with a price target consensus of $59.83, implying a 40.2% upside from current levels. In a report issued on January 2, Morgan Stanley also downgraded the stock to Hold with a $49 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts